{
  "id": 18230186,
  "title": "Arcutis Biotherapeutics EVP, CMO, sells $30,047 in shares",
  "url": "https://urgent.news/2026/11/05/arcutis-biotherapeutics-evp-cmo-sells-30-047-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-05T02:30:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/arcutis-biotherapeutics-evp-cmo-sells-30047-in-shares-93CH-5002052"
  },
  "original_language": "en",
  "account": "Patrick Burnett, Executive Vice President and Chief Medical Officer at Arcutis Biotherapeutics, sold 943 shares of the company's common stock on November 2, 2026. The transaction was valued at $30,047, with shares exchanged at prices fluctuating between $31.57 and $32.23. The sale was made to satisfy tax obligations related to the vesting of restricted stock units. Post this transaction, Mr. Burnett retains ownership of 116,649 shares of Arcutis Biotherapeutics common stock. The shares traded at a price near the 52-week high of $34.80, marking a significant 45% increase over the past six months. However, InvestingPro analysis suggests the stock may be slightly overvalued in relation to its Fair Value. For those interested in a deeper analysis, the company’s Pro Research Report, along with 15 additional ProTips, is available exclusively on InvestingPro. Meanwhile, Arcutis Biotherapeutics reported its third-quarter 2026 financial results on the same day. The company surpassed revenue expectations, reporting $143.9 million, a 45% increase from the previous year's same period, primarily due to robust demand for its product, ZORYVE. Nevertheless, the company's earnings per share were adjusted to $0.06, considerably lower than the $0.18 projected by analysts. This earnings shortfall was primarily due to continued heavy expenditures. This news has drawn the attention of investors and analysts, with a closer look at the company's financial strategies being scrutinized.",
  "summary": null,
  "key_points": [
    "EVP and CMO Patrick Burnett sold 943 shares of Arcutis Biotherapeutics on November 2, 2026.",
    "Sale valued at $30,047, shares traded between $31.57 and $32.23.",
    "Burnett retains 116,649 shares after transaction, stock near 52-week high."
  ],
  "editors_take": "The executive's sale to cover tax obligations occurs alongside a revenue surge and earnings miss, highlighting the tension between strong product demand and the high costs of company growth.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}